tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

INAB Stock Latest News

IN8bio price target adjusted to $4 from $60 at Mizuho
The FlyIN8bio price target adjusted to $4 from $60 at Mizuho
3d ago
INAB
Positive Outlook on IN8bio: Buy Rating Backed by Promising Pipeline Developments and Strategic Financial Adjustments
PremiumRatings
Positive Outlook on IN8bio: Buy Rating Backed by Promising Pipeline Developments and Strategic Financial Adjustments
2M ago
INAB
In8bio, Inc. Reports Improved Financial Performance
PremiumCompany Announcements
In8bio, Inc. Reports Improved Financial Performance
2M ago
INAB
IN8bio reports Q2 EPS ($1.24), consensus ($1.80)
PremiumThe Fly
IN8bio reports Q2 EPS ($1.24), consensus ($1.80)
2M ago
INAB
IN8bio Regains Nasdaq Compliance with Bid Price Rule
PremiumCompany Announcements
IN8bio Regains Nasdaq Compliance with Bid Price Rule
4M ago
8K
INAB
IN8bio recognizes 4-years in remission for patient treated with INB-200
PremiumThe FlyIN8bio recognizes 4-years in remission for patient treated with INB-200
4M ago
INAB
IN8bio Inc trading halted, news pending
Premium
The Fly
IN8bio Inc trading halted, news pending
4M ago
INAB
IN8bio Announces 1-for-30 Reverse Stock Split
Premium
Company Announcements
IN8bio Announces 1-for-30 Reverse Stock Split
4M ago
8K
INAB
IN8bio’s Promising Clinical Trial Results and Strategic Developments Justify Buy Rating
PremiumRatings
IN8bio’s Promising Clinical Trial Results and Strategic Developments Justify Buy Rating
5M ago
INAB
IN8bio Announces Positive Phase 1 Trial Results
PremiumCompany Announcements
IN8bio Announces Positive Phase 1 Trial Results
5M ago
8K
INAB
IN8bio presents Phase 1 data on INB-200 in newly diagnosed GBM
PremiumThe Fly
IN8bio presents Phase 1 data on INB-200 in newly diagnosed GBM
5M ago
INAB
IN8bio’s Promising Preclinical Data and Strategic Partnerships Drive Buy Rating
PremiumRatings
IN8bio’s Promising Preclinical Data and Strategic Partnerships Drive Buy Rating
5M ago
INAB
IN8bio announces preclinical data from its INB-619 program
PremiumThe FlyIN8bio announces preclinical data from its INB-619 program
5M ago
INAB
IN8bio presents data on DeltEx Allo manufacturing program
Premium
The Fly
IN8bio presents data on DeltEx Allo manufacturing program
5M ago
INAB
IN8bio Approves Key Proposals at Annual Meeting
Premium
Company Announcements
IN8bio Approves Key Proposals at Annual Meeting
5M ago
8K
INAB
IN8bio’s Strategic Growth and Development: Buy Rating Affirmed by Soumit Roy
PremiumRatings
IN8bio’s Strategic Growth and Development: Buy Rating Affirmed by Soumit Roy
5M ago
INAB
Promising Developments and Financial Stability Support Buy Rating for IN8bio
PremiumRatings
Promising Developments and Financial Stability Support Buy Rating for IN8bio
5M ago
INAB
IN8bio Reports Q1 2025 Financial Results Amid Cost-Cutting Measures
PremiumCompany Announcements
IN8bio Reports Q1 2025 Financial Results Amid Cost-Cutting Measures
5M ago
INAB
IN8bio reports Q1 EPS (7c), consensus (7c)
PremiumThe Fly
IN8bio reports Q1 EPS (7c), consensus (7c)
5M ago
INAB
IN8bio’s Promising T Cell Engager Program and Strategic Developments Earns Buy Rating
PremiumRatingsIN8bio’s Promising T Cell Engager Program and Strategic Developments Earns Buy Rating
6M ago
INAB
IN8bio announces new preclinical data from gamma-delta T cell engager platform
Premium
The Fly
IN8bio announces new preclinical data from gamma-delta T cell engager platform
6M ago
INAB
IN8bio’s Promising Leukemia Program and Strategic Partnerships Drive Buy Rating
Premium
Ratings
IN8bio’s Promising Leukemia Program and Strategic Partnerships Drive Buy Rating
7M ago
INAB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >